Bispecific antibody cancer therapy market seen hitting $21.76 billion by 2030

The bispecific antibody cancer therapy market is projected to grow from $7.71 billion in 2025 to $21.76 billion by 2030, driven by rising cancer cases, precision immunotherapy demand and expanding pipeline development. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Bispecific antibody cancer therapy is gaining traction as oncology shifts toward more precise treatments that can bind cancer cells and immune cells at the same time. - The market’s projected rise to $21.76 billion by 2030 signals stronger demand for therapies that could improve patient outcomes across multiple cancer types. - The growth outlook also reflects a broader push into engineered antibody technologies and combination immunotherapy regimens.

What happened: - The Business Research Company published a new report on the bispecific antibody cancer therapy market, covering market size, trends and global forecasts for 2026-2035. - The report says the market will grow from $7.71 billion in 2025 to $9.48 billion in 2026, a 22.9% CAGR. - The same report projects the market will reach $21.76 billion by 2030, with a 23.1% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Bispecific antibody cancer therapy uses engineered antibodies that bind two distinct antigens at once, usually one on a cancer cell and one on an immune cell. - The dual-targeting design is meant to redirect and activate the immune system against tumors. - The therapy is positioned for use in precision oncology and immuno-oncology. - The report identifies rising cancer prevalence as a major growth driver. - The World Health Organization projected more than 35 million new cancer cases by 2050, up 77% from an estimated 20 million cases in 2022. - Other growth factors include more research into immunotherapy, more clinical trials for bispecific antibodies and continued antibody engineering improvements. - The report points to greater use of combination regimens that pair bispecific antibodies with other immunotherapies. - Key future trends include trispecific antibody constructs, dual checkpoint inhibition in solid tumors, nanobody-based bispecific platforms, bispecific antibody drug conjugates and personalized immuno-oncology regimens using engineered T cell engager antibodies. - The geographic scope includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company also highlighted new 2026 report features, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - The report offers a free sample and the full market report.

Between the lines: - The market forecast suggests investors and drug developers see bispecific antibodies as one of the most promising ways to improve targeted cancer treatment. - The emphasis on pipeline development and next-generation engineering indicates competition is moving beyond first-generation therapies. - Faster growth in Asia-Pacific points to expanding demand in markets with rising cancer burdens and improving access to advanced diagnostics and therapies.

What's next: - The report expects sustained expansion through 2030 as precision immunotherapy, personalized treatment strategies and combination regimens continue to advance. - Progress in solid tumor targeting and engineered antibody platforms is likely to shape which companies gain share next. - Clinical development and commercialization activity will likely remain centered on therapies that improve efficacy while expanding patient options.

The bottom line: - Bispecific antibody cancer therapy is moving from a niche oncology approach toward a high-growth global market, with cancer prevalence and immunotherapy innovation driving the next phase of expansion.